We are pleased to share that our t:slim X2™ insulin pump with Basal-IQ® technology will be used by long-distance runner Don Muchow on his #T1Determined Type 1 Diabetes Run Across America. Starting February 1, 2020, Muchow will attempt to become the fastest person with type 1 diabetes ever to run across the Continental United States.
“Many people with diabetes struggle to incorporate exercise into their daily routine because of a fear of low blood sugars,” said Muchow. “I want to demonstrate that there is a safe way for people with diabetes to incorporate exercise into their daily routine.”
Muchow wears the t:slim X2 insulin pump with Basal-IQ technology which uses Dexcom G6 CGM† values to help reduce the frequency and duration of low-glucose events by predicting glucose levels 30 minutes ahead and suspending insulin if needed.
The #T1Determined Type 1 Diabetes Run Across America starts on February 1, 2020 at 6:00am PST in Newport Beach CA, and plans to finish on May 8, 2020 in Melbourne, Florida. Muchow believes he can accomplish his newest journey of more than 2,830 miles in no more than 100 days. Those interested in route details, and Muchow’s progress, can follow along with a live GPS satellite tracking link posted at his website www.t1determined.org
Diagnosed with type 1 diabetes 47 years ago, Muchow wasn’t always active. He started running in 2004 after a laser treatment for diabetes-related retinopathy. Since then, he has run in more than 30 triathlons, century bike rides, ultra marathons and relay races, marathons and half-marathons.
“I promised myself if I had a do-over, I’d jump on it and never look back,” he said. “I want to highlight what people with type 1 diabetes are capable of if they set their minds to it. With my diabetes technology, I want to set the record as the first person in history to run from Disneyland to Disney World.”
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump available with predictive low glucose suspend or advanced hybrid closed loop technologies. The t:slim X2 pump is capable of remote feature updates using a personal computer. Tandem is based in San Diego, California.
Important Safety Information:
Caution: Federal (USA) law restricts the t:slim X2 insulin pump and the t:slim X2 pump with Basal-IQ technology to sale by or on the order of a physician.
Indications for Use:
t:slim X2 insulin pump
The t:slim X2 insulin pump with interoperable technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in individuals 6 years of age and greater. The pump is intended for single patient use. The pump is indicated for use with NovoLog or Humalog U-100 insulin.
t:slim X2 insulin pump with Basal-IQ technology
When used with a compatible integrated continuous glucose monitor (iCGM), the t:slim X2 insulin pump with Basal-IQ technology can be used to suspend insulin delivery based on CGM sensor readings. The t:slim X2 pump with Basal-IQ technology is indicated for use in individuals 6 years of age and greater. The t:slim X2 pump with Basal-IQ technology is intended for single patient use. The t:slim X2 pump with Basal-IQ technology is indicated for use with NovoLog or Humalog U-100 insulin.
Contraindications and Warnings:
The t:slim X2 pump with Basal-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients.
Users of the t:slim X2 pump and the t:slim X2 pump with Basal-IQ technology must:
• be able and willing to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use;
• test blood glucose levels as recommended by their healthcare provider;
• demonstrate adequate carb-counting skills;
• maintain sufficient diabetes self-care skills;
• see healthcare provider(s) regularly; and
• have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders;
The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo
for additional important safety information.
Tandem Diabetes Care and Basal-IQ are registered trademarks, and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.
† CGM sold separately.
Tandem Diabetes Care Contact Information:
Media: Steve Sabicer, 714-907-6264, email@example.com